Annals of Surgical Oncology

, Volume 24, Issue 9, pp 2655–2668 | Cite as

Prognostic Role of Primary Tumor Location in Non-Metastatic Gastric Cancer: A Systematic Review and Meta-Analysis of 50 Studies

  • Fausto Petrelli
  • Michele Ghidini
  • Sandro Barni
  • Francesca Steccanella
  • Giovanni Sgroi
  • Rodolfo Passalacqua
  • Gianluca Tomasello
Gastrointestinal Oncology

Abstract

Introduction

The incidence of gastric cancer (GC) arising in the upper third of the stomach, including the cardia or gastroesophageal junction (GEJ), has increased in the last decades due to established etiological risk factors such as diet, obesity, and gastroesophageal reflux. We conducted a systematic review and meta-analysis to determine the prognostic role of site of origin in patients with proximal versus distal GC.

Material and Methods

We conducted a search of the PubMed, Cochrane Library, SCOPUS, Web of Science, EMBASE, Google Scholar, LILACS, and CINAHL databases from inception to September 2016. Studies reporting data on the independent prognostic effect of site in GC and comparing overall survival (OS) in proximal versus distal tumors were eligible. Data were pooled using OS hazard ratios (HRs) of proximal versus distal GC according to fixed- or random-effect model.

Results

Overall, 50 studies including 128,268 patients were identified. Cancers located in the upper third of the stomach were associated with a significantly increased risk of all-cause mortality (HR 1.31, 95% confidence interval [CI] 1.17–1.46, p < 0.001, I 2 = 91%). After exclusion of GEJ tumors, prognosis was worse for pure cardia location (HR 1.39, 95% CI 1.22–1.58, p < 0.001, I 2 = 61%) compared with proximal or upper-third GCs without a specific subsite definition (HR 1.18, 95% CI 1.01–1.37, p = 0.04, I 2 = 91%).

Conclusions

Location of the primary GC in the upper third of the stomach, particularly at the GEJ/cardia, should be acknowledged as an important prognostic factor. Based on these results, more effective treatment strategies for proximal GCs are needed.

Keywords

Gastric Cancer Overall Survival Human Epidermal Growth Factor Receptor Proximal Tumor Gastric Cardia 

Notes

Disclosure

Fausto Petrelli, Michele Ghidini, Sandro Barni, Francesca Steccanella, Giovanni Sgroi, Rodolfo Passalacqua, and Gianluca Tomasello declare no conflict of interest.

References

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Colquhoun A, Arnold M, Ferlay J, Goodman KJ, Forman D, Soerjomataram I. Global patterns of cardia and non-cardia gastric cancer incidence in 2012. Gut. 2015;64(12):1881–88.CrossRefPubMedGoogle Scholar
  3. 3.
    Dupont JB Jr, Lee JR, Burton GR, Cohn I Jr. Adenocarcinoma of the stomach: review of 1,497 cases. Cancer. 1978;41(3):941–47.CrossRefPubMedGoogle Scholar
  4. 4.
    Kampschoer GH, Nakajima T, van de Velde CJ. Changing patterns in gastric adenocarcinoma. Br J Surg. 1989;76(9):914–16.CrossRefPubMedGoogle Scholar
  5. 5.
    Powell J, McConkey CC. Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. Br J Cancer. 1990;62(3):440–43.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Hansen S, Vollset SE, Derakhshan MH, et al. Two distinct aetiologies of cardia cancer; evidence from premorbid serological markers of gastric atrophy and Helicobacter pylori status. Gut. 2007;56(7):918–25.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Kalish RJ, Clancy PE, Orringer MB, Appelman HD. Clinical, epidemiologic, and morphologic comparison between adenocarcinomas arising in Barrett’s esophageal mucosa and in the gastric cardia. Gastroenterology. 1984;86(3):461–67.PubMedGoogle Scholar
  8. 8.
    Edge S, Byrd D, Compton C. American Joint Committee on cancer staging manual. 7th ed. Ann Surg Oncol. 2010;17(6):1471–74.CrossRefPubMedGoogle Scholar
  9. 9.
    Van Laethem JL, Carneiro F, Ducreux M, et al. The multidisciplinary management of gastro-oesophageal junction tumours: European Society of Digestive Oncology (ESDO): expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, Barcelona. Dig Liver Dis. 2016;48(11):1283–89.CrossRefPubMedGoogle Scholar
  10. 10.
    Pacelli F, Papa V, Caprino P, Sgadari A, Bossola M, Doglietto GB. Proximal compared with distal gastric cancer: multivariate analysis of prognostic factors. Am Surg. 2001;67(7):697–703.PubMedGoogle Scholar
  11. 11.
    Wells G, Shea B, O’Connell D. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. 2015. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 29 Dec 2015.
  12. 12.
    Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–01.CrossRefPubMedGoogle Scholar
  13. 13.
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455–63.CrossRefPubMedGoogle Scholar
  15. 15.
    Bajetta E, Buzzoni R, Mariani L, et al. Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Ann Oncol. 2002;13(2):299–307.CrossRefPubMedGoogle Scholar
  16. 16.
    Bamboat ZM, Tang LH, Vinuela E, et al. Stage-stratified prognosis of signet ring cell histology in patients undergoing curative resection for gastric adenocarcinoma. Ann Surg Oncol. 2014;21(5):1678–85.CrossRefPubMedGoogle Scholar
  17. 17.
    Bani-Hani KE, Almasri NM, Khader YS, Sheyab FM, Karam HN. Combined evaluation of expressions of cyclin E and p53 proteins as prognostic factors for patients with gastric cancer. Clin Cancer Res. 2005;11(4):1447–53.CrossRefPubMedGoogle Scholar
  18. 18.
    Bilici A, Seker M, Ustaalioglu BB, et al. Prognostic significance of perineural invasion in patients with gastric cancer who underwent curative resection. Ann Surg Oncol. 2010;17(8):2037–44.CrossRefPubMedGoogle Scholar
  19. 19.
    Bouche O, Ychou M, Burtin P, et al. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol. 2005;16(9):1488–97.CrossRefPubMedGoogle Scholar
  20. 20.
    Bruno L, Nesi G, Nobili S, et al. Postoperative chemotherapy in resected gastric cancer: results of a single center experience. J Chemother. 2008;20(4):497–502.CrossRefPubMedGoogle Scholar
  21. 21.
    Caruso RA, Bellocco R, Pagano M, Bertoli G, Rigoli L, Inferrera C. Prognostic value of intratumoral neutrophils in advanced gastric carcinoma in a high-risk area in northern Italy. Mod Pathol. 2002;15(8):831–37.CrossRefPubMedGoogle Scholar
  22. 22.
    Chou HH, Kuo CJ, Hsu JT, et al. Clinicopathologic study of node-negative advanced gastric cancer and analysis of factors predicting its recurrence and prognosis. Am J Surg. 2013;205(6):623–30.CrossRefPubMedGoogle Scholar
  23. 23.
    Datta J, Lewis RS Jr, Mamtani R, et al. Implications of inadequate lymph node staging in resectable gastric cancer: a contemporary analysis using the National Cancer Data Base. Cancer. 2014;120(18):2855–65.CrossRefPubMedGoogle Scholar
  24. 24.
    Deans C, Yeo MS, Soe MY, Shabbir A, Ti TK, So JB. Cancer of the gastric cardia is rising in incidence in an Asian population and is associated with adverse outcome. World J Surg. 2011;35(3):617–24.CrossRefPubMedGoogle Scholar
  25. 25.
    Fiteni F, Paget-Bailly S, Messager M, et al. Docetaxel, cisplatin, and 5-fluorouracil as perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma. Cancer Med. 2016;5(11):3085–93.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Gu J, Zheng L, Zhang L, et al. TFF3 and HER2 expression and their correlation with survival in gastric cancer. Tumour Biol. 2015;36(4):3001–07.CrossRefPubMedGoogle Scholar
  27. 27.
    Han DS, Suh YS, Kong SH, et al. Nomogram predicting long-term survival after d2 gastrectomy for gastric cancer. J Clin Oncol. 2012;30(31):3834–40.CrossRefPubMedGoogle Scholar
  28. 28.
    Hsu JT, Lin CJ, Sung CM, et al. Prognostic significance of the number of examined lymph nodes in node-negative gastric adenocarcinoma. Eur J Surg Oncol. 2013;39(11):1287–93.CrossRefPubMedGoogle Scholar
  29. 29.
    In H, Kantor O, Sharpe SM, Baker MS, Talamonti MS, Posner MC. Adjuvant therapy improves survival for T2N0 gastric cancer patients with sub-optimal lymphadenectomy. Ann Surg Oncol. 2016;23(6):1956–62.CrossRefPubMedGoogle Scholar
  30. 30.
    Jacome AA, Wohnrath DR, Scapulatempo Neto C, et al. Effect of adjuvant chemoradiotherapy on overall survival of gastric cancer patients submitted to D2 lymphadenectomy. Gastric Cancer. 2013;16(2):233–238.CrossRefPubMedGoogle Scholar
  31. 31.
    Kang SY, Han JH, Ahn MS, et al. Helicobacter pylori infection as an independent prognostic factor for locally advanced gastric cancer patients treated with adjuvant chemotherapy after curative resection. Int J Cancer. 2012;130(4):948–58.CrossRefPubMedGoogle Scholar
  32. 32.
    Kim MA, Lee HS, Yang HK, Kim WH. Clinicopathologic and protein expression differences between cardia carcinoma and noncardia carcinoma of the stomach. Cancer. 2005;103(7):1439–46.CrossRefPubMedGoogle Scholar
  33. 33.
    Kunz PL, Gubens M, Fisher GA, Ford JM, Lichtensztajn DY, Clarke CA. Long-term survivors of gastric cancer: a California population-based study. J Clin Oncol. 2012;30(28):3507–15.CrossRefPubMedGoogle Scholar
  34. 34.
    Kurokawa Y, Matsuura N, Kimura Y, et al. Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer. Gastric Cancer. 2015;18(4):691–97.CrossRefPubMedGoogle Scholar
  35. 35.
    Lee JW, Ali B, Park CH, Song KY. Different lymph node staging systems in patients with gastric cancer from Korean: what is the best prognostic assessment tool? Medicine. 2016;95(25):e3860.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Liu C, Lu P, Lu Y, Xu H, Wang S, Chen J. Clinical implications of metastatic lymph node ratio in gastric cancer. BMC Cancer. 2007;7:200.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Liu K, Zhang W, Chen X, et al. Comparison on clinicopathological features and prognosis between esophagogastric junctional adenocarcinoma (Siewert II/III types) and distal gastric adenocarcinoma: retrospective cohort study, a single institution, high volume experience in china. Medicine. 2015;94(34):e1386.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Marchet A, Mocellin S, Ambrosi A, et al. The ratio between metastatic and examined lymph nodes (N ratio) is an independent prognostic factor in gastric cancer regardless of the type of lymphadenectomy: results from an Italian multicentric study in 1853 patients. Ann Surg. 2007;245(4):543–52.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Marrelli D, Pedrazzani C, Berardi A, et al. Negative Helicobacter pylori status is associated with poor prognosis in patients with gastric cancer. Cancer. 2009;115(10):2071–80.CrossRefPubMedGoogle Scholar
  40. 40.
    McGhan LJ, Pockaj BA, Gray RJ, Bagaria SP, Wasif N. Validation of the updated 7th edition AJCC TNM staging criteria for gastric adenocarcinoma. J Gastrointest Surg. 2012;16(1):53–61; discussion 61.CrossRefPubMedGoogle Scholar
  41. 41.
    Nakagawa M, Inokuchi M, Takagi Y, et al. Erythropoietin-producing hepatocellular A1 is an independent prognostic factor for gastric cancer. Ann Surg Oncol. 2015;22(7):2329–35.CrossRefPubMedGoogle Scholar
  42. 42.
    Nelen SD, van Steenbergen LN, Dassen AE, van der Wurff AA, Lemmens VE, Bosscha K. The lymph node ratio as a prognostic factor for gastric cancer. Acta Oncol. 2013;52(8):1751-1759.CrossRefPubMedGoogle Scholar
  43. 43.
    Park ES, Do IG, Park CK, et al. Cyclooxygenase-2 is an independent prognostic factor in gastric carcinoma patients receiving adjuvant chemotherapy and is not associated with EBV infection. Clin Cancer Res. 2009;15(1):291–98.CrossRefPubMedGoogle Scholar
  44. 44.
    Pedrazzani C, Sivins A, Ancans G, et al. Ratio between metastatic and examined lymph nodes (N ratio) may have low clinical utility in gastric cancer patients treated by limited lymphadenectomy: results from a single-center experience of 526 patients. World J Surg. 2010;34(1):85–91.CrossRefPubMedGoogle Scholar
  45. 45.
    Persiani R, D’Ugo D, Rausei S, et al. Prognostic indicators in locally advanced gastric cancer (LAGC) treated with preoperative chemotherapy and D2-gastrectomy. J Surg Oncol. 2005;89(4):227–36; discussion 237–228.CrossRefPubMedGoogle Scholar
  46. 46.
    Piessen G, Messager M, Leteurtre E, Jean-Pierre T, Mariette C. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Ann Surg. 2009;250(6):878–87.CrossRefPubMedGoogle Scholar
  47. 47.
    Posteraro B, Persiani R, Dall’Armi V, et al. Prognostic factors and outcomes in Italian patients undergoing curative gastric cancer surgery. Eur J Surg Oncol. 2014;40(3):345–51.CrossRefPubMedGoogle Scholar
  48. 48.
    Postlewait LM, Squires MH 3rd, Kooby DA, et al. The prognostic value of signet-ring cell histology in resected gastric adenocarcinoma. Ann Surg Oncol. 2015;22 Suppl 3:S832–39.CrossRefPubMedGoogle Scholar
  49. 49.
    Qiu MZ, Qiu HJ, Wang ZQ, et al. The tumor-log odds of positive lymph nodes-metastasis staging system, a promising new staging system for gastric cancer after D2 resection in China. PloS One. 2012;7(2):e31736.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Rodriguez Santiago JM, Munoz E, Marti M, Quintana S, Veloso E, Marco C. Metastatic lymph node ratio as a prognostic factor in gastric cancer. Eur J Surg Oncol. 2005;31(1):59–66.CrossRefPubMedGoogle Scholar
  51. 51.
    Rohatgi PR, Yao JC, Hess K, et al. Outcome of gastric cancer patients after successful gastrectomy: influence of the type of recurrence and histology on survival. Cancer. 2006;107(11):2576–80.CrossRefPubMedGoogle Scholar
  52. 52.
    Shen GS, Zhao JD, Zhao JH, et al. Association of HER2 status with prognosis in gastric cancer patients undergoing R0 resection: a large-scale multicenter study in China. World J Gastroenterol. 2016;22(23):5406–14.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Shen JY, Kim S, Cheong JH, et al. The impact of total retrieved lymph nodes on staging and survival of patients with pT3 gastric cancer. Cancer. 2007;110(4):745–51.CrossRefPubMedGoogle Scholar
  54. 54.
    Shim JH, Song KY, Jeon HM, et al. Is gastric cancer different in Korea and the United States? Impact of tumor location on prognosis. Ann Surg Oncol. 2014;21(7):2332–39.CrossRefPubMedGoogle Scholar
  55. 55.
    Smyth EC, Capanu M, Janjigian YY, et al. Tobacco use is associated with increased recurrence and death from gastric cancer. Ann Surg Oncol. 2012;19(7):2088–94.CrossRefPubMedGoogle Scholar
  56. 56.
    Song HJ, Srivastava A, Lee J, et al. Host inflammatory response predicts survival of patients with Epstein-Barr virus-associated gastric carcinoma. Gastroenterology. 2010;139(1):84–92.CrossRefPubMedGoogle Scholar
  57. 57.
    Squires MH 3rd, Kooby DA, Poultsides GA, et al. Effect of perioperative transfusion on recurrence and survival after gastric cancer resection: a 7-institution analysis of 765 patients from the US Gastric Cancer Collaborative. J Am Coll Surg. 2015;221(3):767–77.CrossRefPubMedGoogle Scholar
  58. 58.
    Strauss J, Hershman DL, Buono D, et al. Use of adjuvant 5-fluorouracil and radiation therapy after gastric cancer resection among the elderly and impact on survival. Int J Radiat Oncol Biol Phys. 2010;76(5):1404–12.CrossRefPubMedGoogle Scholar
  59. 59.
    Tsujimoto H, Ichikura T, Ono S, et al. Impact of postoperative infection on long-term survival after potentially curative resection for gastric cancer. Ann Surg Oncol. 2009;16(2):311–18.CrossRefPubMedGoogle Scholar
  60. 60.
    Wang SC, Chou JF, Strong VE, Brennan MF, Capanu M, Coit DG. Pretreatment neutrophil to lymphocyte ratio independently predicts disease-specific survival in resectable gastroesophageal junction and gastric adenocarcinoma. Ann Surg. 2016;263(2):292–97.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Wu H-L, Tian Q, Peng C-W, Liu S-P, Li Y. Multivariate survival and outcome analysis of 154 patients with gastric cancer at single Chinese institution. Asian Pacific J Cancer Prev. 2011;12:3341–45.Google Scholar
  62. 62.
    Xu D, Huang Y, Geng Q, et al. Effect of lymph node number on survival of patients with lymph node-negative gastric cancer according to the 7th edition UICC TNM system. PloS ONE. 2012;7(6):e38681.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Yu J, Zeng Z, Wang S, et al. IL-1B-511 polymorphism is associated with increased risk of certain subtypes of gastric cancer in Chinese: a case-control study. Am J Gastroenterol. 2010;105(3):557–64.CrossRefPubMedGoogle Scholar
  64. 64.
    Zhu HP, Xia X, Yu CH, Adnan A, Liu SF, Du YK. Application of Weibull model for survival of patients with gastric cancer. BMC Gastroenterol. 2011;11:1.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Fang X, Wei J, He X, An P, Wang H, Jiang L, et al. Landscape of dietary factors associated with risk of gastric cancer: a systematic review and dose-response meta-analysis of prospective cohort studies. Eur J Cancer. 2015;51(18):2820–32.CrossRefPubMedGoogle Scholar
  66. 66.
    Chen XZ, Chen H, Castro FA, Hu JK, Brenner H. Epstein-Barr virus infection and gastric cancer: a systematic review. Medicine (Baltimore). 2015;94(20):e792.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Zeng W, Zhu J, Shan L, Han Z, Aerxiding P, Quhai A, et al. The clinicopathological significance of CDH1 in gastric cancer: a meta-analysis and systematic review. Drug Des Devel Ther. 2015;9:2149–57.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Lui FH, Tuan B, Swenson SL, Wong RJ. Ethnic disparities in gastric cancer incidence and survival in the USA: an updated analysis of 1992-2009 SEER data. Dig Dis Sci. 2014;59(12):3027–34.CrossRefPubMedGoogle Scholar
  69. 69.
    Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum. 1994;61:1–241.Google Scholar
  70. 70.
    Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.CrossRefPubMedGoogle Scholar
  71. 71.
    Shah MA, Kelsen DP. Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. J Natl Compr Canc Netw. 2010;8(4):437–47.CrossRefPubMedGoogle Scholar
  72. 72.
    Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345(11):784–89.CrossRefPubMedGoogle Scholar
  73. 73.
    Hamilton JP, Meltzer SJ. A review of the genomics of gastric cancer. Clin Gastroenterol Hepatol. 2006;4(4):416–25.CrossRefPubMedGoogle Scholar
  74. 74.
    Kamangar F, Dawsey SM, Blaser MJ, et al. Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. J Natl Cancer Inst. 2006;98(20):1445–52.CrossRefPubMedGoogle Scholar
  75. 75.
    Ye W, Held M, Lagergren J, et al. Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer Inst. 2004;96(5):388–96.CrossRefPubMedGoogle Scholar
  76. 76.
    Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–09.CrossRefGoogle Scholar
  77. 77.
    Sakaguchi T, Watanabe A, Sawada H, et al. Characteristics and clinical outcome of proximal-third gastric cancer. J Am Coll Surg. 1998;187(4):352–57.CrossRefPubMedGoogle Scholar
  78. 78.
    Harrison LE, Karpeh MS, Brennan MF. Proximal gastric cancers resected via a transabdominal-only approach. Results and comparisons to distal adenocarcinoma of the stomach. Ann Surg. 1997;225(6):678-683; discussion 683-675.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Siewert JR, Bottcher K, Stein HJ, Roder JD, Busch R. Problem of proximal third gastric carcinoma. World J Surg. 1995;19(4):523–31.CrossRefPubMedGoogle Scholar
  80. 80.
    Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.CrossRefPubMedGoogle Scholar
  81. 81.
    Barros-Silva JD, Leitao D, Afonso L, et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer. 2009;100(3):487–93.CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Tanner M, Hollmen M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: association with topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005;16(2):273–78.CrossRefPubMedGoogle Scholar
  83. 83.
    Aizawa M, Nagatsuma AK, Kitada K, et al. Evaluation of HER2-based biology in 1,006 cases of gastric cancer in a Japanese population. Gastric Cancer. 2014;17(1):34–42.CrossRefPubMedGoogle Scholar
  84. 84.
    Janjigian YY, Werner D, Pauligk C, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol. 2012;23(10):2656–62.CrossRefPubMedGoogle Scholar
  85. 85.
    Terashima M, Kitada K, Ochiai A, et al. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res. 2012;18(21):5992–6000.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2017

Authors and Affiliations

  • Fausto Petrelli
    • 1
  • Michele Ghidini
    • 2
  • Sandro Barni
    • 1
  • Francesca Steccanella
    • 3
  • Giovanni Sgroi
    • 3
  • Rodolfo Passalacqua
    • 2
  • Gianluca Tomasello
    • 2
  1. 1.Oncology Unit, Oncology DepartmentASST Bergamo OvestTreviglio (BG)Italy
  2. 2.Oncology Unit, Oncology DepartmentASST Ospedale di CremonaCremonaItaly
  3. 3.Surgical Oncology Unit, Surgery DepartmentASST Bergamo OvestTreviglio (BG)Italy

Personalised recommendations